Chronic kidney disease
Conditions
Interventions
High dose treatment group:Shenqi Shenshuai mixture
Low dose treatment group:10% concentration of Shenqi Shenshuai mixture
Sponsors
Wuhan NO.1 Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for stage 3 chronic kidney disease; (2) Traditional Chinese medicine syndrome differentiation belongs to spleen kidney qi deficiency combined with blood stasis and dampness turbidity syndrome; (3) Gender not limited, age greater than or equal to 18 years old and less than 80 years old; (4) Not receiving dialysis treatment; (5) Sign the informed consent form, with complete general and clinical information; (6) Be able to comply with the research procedures specified in the protocol.
Exclusion criteria
Exclusion criteria: (1) Patients with acute exacerbation of chronic renal failure; (2) Patients with diabetes; (3) Patients with large amounts of proteinuria (24-hour urine protein quantification = 3.5g or total urine protein/creatinine = 3.5g/g); (4) Low density lipoprotein (LDL) = twice the normal reference range; (5) Poor control of hypertension (using standard measurement methods under quiet and awake conditions, with at least 3 non same day systolic blood pressure = 160mmHg and/or diastolic blood pressure = 100 mmHg, or at least 1 blood pressure SBP = 180mmHg and/or DBP = 110 mmHg); (6) During the medication period, patients who have used Chinese herbal medicine or drugs indicated on the drug instructions as having an impact on kidney function; (7) Patients who are pregnant, breastfeeding, or have pregnancy plans; (8) Merge patients with serious complications such as severe infections, severe cardiovascular and cerebrovascular diseases, gastrointestinal bleeding, and malignant tumors; (9) Patients with a history of mental illness or poor compliance who cannot be treated according to the plan; (10) Patients who participate in other clinical trials during medication. (11) The researchers believe that there are any other patients who are not suitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annual average decline rate of glomerular filtration rate (eGFR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in clinical efficacy score;TCM syndrome score;TCM main syndrome score;secondary syndrome score;total syndrome score;hemoglobin;Total Protein;albumin;serum creatinine;Blood Urea Nitrogen;serum kalium;serum calcium;serum phosphorus;Cystatin C;cholesterol;triglyceride;High density lipoprotein;Low density lipoprotein;Serum ferritin;C-reactive protein;IL-1ß;IL-6;TNF-a;IL-10; | — |
Countries
China
Contacts
Public ContactXiong Fei
Wuhan NO.1 Hospital
Outcome results
None listed